This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mylan Specialty L.P. Announces 25th Anniversary Celebration Of EpiPen® (epinephrine) Auto-Injector

BASKING RIDGE, N.J., April 25, 2013 /PRNewswire/ -- Mylan Specialty L.P., the fully integrated specialty pharmaceutical business of Mylan Inc. (Nasdaq: MYL), is celebrating the 25 th anniversary of the U.S. Food and Drug Administration's (FDA) approval of the EpiPen ® (epinephrine) Auto-Injector. This innovative epinephrine auto-injector, the first of its kind, was developed for the emergency treatment of severe allergic reactions (anaphylaxis). Today, with more than 46 million EpiPen Auto-Injectors dispensed, it remains the No. 1 prescribed epinephrine auto-injector.

In recognition of this important milestone, Mylan Specialty recently introduced the 25 th anniversary " $0 Co-Pay Offer." As is consistent with Mylan's commitment to providing people access to high quality medicine, this co-pay card is available to both cash-paying and commercially insured patients. Certain restrictions apply. Additional information about the co-pay card is available online at, and the coupon is available to patients through physicians across the country. The " $0 Co-Pay Offer" is valid for up to three EpiPen 2-Pak ® cartons or EpiPen Jr 2-Pak ® cartons per prescription, as patients may need to access two EpiPen or EpiPen Jr ® (epinephrine) Auto-Injectors in multiple locations. Eligible patients can use the offer with an unlimited number of prescriptions until the coupon offer expires on December 31, 2013. 

"Mylan has a long-standing dedication to increasing access to epinephrine auto-injectors through innovative access solutions such as the EpiPen4Schools program, and we're pleased to continue that commitment by introducing our $0 Co-Pay Offer," said Heather Bresch, CEO of Mylan.  

Immediate access to epinephrine, the medication delivered by EpiPen Auto-Injector, is a critical component of an anaphylaxis action plan. Since 2009, EpiPen Auto-Injectors have delivered an injection of epinephrine using built-in needle protection, so people never see or are exposed to the needle before and after use. Those known to be at risk for anaphylaxis should have an action plan that includes avoiding known allergens, recognizing symptoms, having access to two epinephrine auto-injectors at all times and seeking immediate emergency medical care should anaphylaxis occur.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.28 -0.94%
FB $117.85 0.36%
GOOG $696.93 0.66%
TSLA $223.69 -3.70%
YHOO $35.91 -0.28%


Chart of I:DJI
DOW 17,650.20 -100.71 -0.57%
S&P 500 2,050.15 -13.22 -0.64%
NASDAQ 4,724.0390 -39.1850 -0.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs